NCT00277238 - CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects | Biotech Hunter

Enrollment

113

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions

Hepatitis, Chronic Active

Interventions

DRUG

CPG10101

CPG10101, subcutaneous, 0.2mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks

DRUG

CPG10101

CPG10101, subcutaneous, 0.5mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks

DRUG

Control

Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 12wks

DRUG

CPG10101

CPG10101, subcutaneous, 0.5mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks

Trial Locations (14)

10021

Pfizer Investigational Site, New York

17033

Pfizer Investigational Site, Hershey

23249

Pfizer Investigational Site, Richmond

27710

Pfizer Investigational Site, Durham

38138

Pfizer Investigational Site, Germantown

44195

Pfizer Investigational Site, Cleveland

46202

Pfizer Investigational Site, Indianapolis

60611

Pfizer Investigational Site, Chicago

63104

Pfizer Investigational Site, St Louis

64131

Pfizer Investigational Site, Kansas City

70115

Pfizer Investigational Site, New Orleans

75208

Pfizer Investigational Site, Dallas

78215

Pfizer Investigational Site, San Antonio

48202-2689

Pfizer Investigational Site, Detroit